Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674024 · ClinicalTrials.gov registry record · Phase 1
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00674024: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00674024 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674024, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Background: * Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival. * This is the first study in which pazopanib is given to patients with different degrees of liver function. The safe dose for patients with normal liver function is already known. Objectives: * To determine the safety and side effects of pazopanib given at different dose levels to patients with cancer who have different degrees of liver function. * To find out how much pazopanib is in the blood at specific times. * To determine if pazopanib is effective in treating advanced cancer in patients with different degrees of liver function. Eligibility: \- Patients 18 years of age and older with an advanced solid tumor or lymphoma that cannot be treated successfully with standard therapies and who have normal or abnormal liver function. Design: * Treatment: * Patients are divided into 4 groups, based on their liver function. The first three patients in each group receive a low dose of pazopanib. The next three in each group receive a higher dose of pazopanib if no serious side effects were reported in the previous three. The dose is increased in succeeding groups of three patients until the maximum study dose is reached. * Patients take pazopanib once a day by mouth in 21-day treatment cycles. Treatment continues until the cancer worsens, the patient develops severe side effects, the patient no longer wants to continue the study, or the doctor removes the patient from the study for other reasons. * Monitoring: * Blood pressure: Patients monitor and record their blood pressure twice a day after starting treatment. * Blood tests: Patients have weekly routine blood tests. In addition, at week 3 of the first cycle and again after the highest safe dose has been determined, several blood samples are collected at frequent intervals to determine how the body handles the drug. * Imaging studies: X-r
Interventions
- DRUG Pazopanib
- DRUG Pazopanib (GW786034)(GW786034)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-10-07 |
| Est. Completion | 2013-01-22 |
| Phase | Phase 1 |
What the finished NCT00674024 record still lists
NCT00674024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT00674024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00674024 about?
NCT00674024 is a clinical study titled "Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function". Background: * Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival. * This is the first study in which pazopanib is given to patients with different degrees of liver function. The safe dos...
What is the current status of trial NCT00674024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-10-07. Estimated completion is 2013-01-22.
What interventions are being tested in trial NCT00674024?
The interventions under investigation include: Pazopanib (DRUG), Pazopanib (GW786034)(GW786034) (DRUG).
Who is sponsoring clinical trial NCT00674024?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00674024's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI